

Title (en)  
SUBSTITUTED ACYLGUANIDINE DERIVATIVE

Title (de)  
SUBSTITUIERTES ACYLGUANIDINDERIVAT

Title (fr)  
DÉRIVÉ D'ACYLGUANIDINE SUBSTITUÉ

Publication  
**EP 2394988 A4 20120905 (EN)**

Application  
**EP 10738633 A 20100208**

Priority  
• JP 2010051757 W 20100208  
• JP 2009026855 A 20090209

Abstract (en)  
[origin: EP2394988A1] An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT 5A receptor modulating action. It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT 5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.

IPC 8 full level  
**C07C 279/22** (2006.01); **A61K 31/166** (2006.01); **A61K 31/192** (2006.01); **A61K 31/216** (2006.01); **A61K 31/277** (2006.01); **A61K 31/351** (2006.01); **A61K 31/426** (2006.01); **A61K 31/44** (2006.01); **A61P 25/18** (2006.01); **A61P 25/28** (2006.01); **A61P 43/00** (2006.01); **C07C 317/44** (2006.01); **C07C 323/62** (2006.01); **C07D 213/58** (2006.01); **C07D 213/61** (2006.01); **C07D 277/20** (2006.01); **C07D 277/56** (2006.01); **C07D 307/28** (2006.01); **C07D 309/22** (2006.01)

CPC (source: EP US)  
**A61P 25/00** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07C 279/22** (2013.01 - EP US); **C07C 317/44** (2013.01 - EP US); **C07C 323/62** (2013.01 - EP US); **C07D 213/58** (2013.01 - EP US); **C07D 213/61** (2013.01 - EP US); **C07D 277/20** (2013.01 - EP US); **C07D 277/56** (2013.01 - EP US); **C07D 307/28** (2013.01 - EP US); **C07D 309/22** (2013.01 - EP US); **C07C 2601/02** (2017.04 - EP US)

Citation (search report)  
• [A] EP 1923387 A1 20080521 - ASTELLAS PHARMA INC [JP]  
• [A] WO 2006135978 A1 20061228 - BIOTRON LTD [AU], et al  
• See references of WO 2010090305A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)  
**EP 2394988 A1 20111214**; **EP 2394988 A4 20120905**; JP WO2010090305 A1 20120809; US 2012041036 A1 20120216; WO 2010090305 A1 20100812

DOCDB simple family (application)  
**EP 10738633 A 20100208**; JP 2010051757 W 20100208; JP 2010549528 A 20100208; US 201013148448 A 20100208